In a Nairobi hospital, a young woman's routine surgery became the site of a rare and sobering discovery: a fungus resistant to every antifungal drug medicine currently offers. Only the second case of its kind ever documented, and the first on the African continent, this strain of Candidozyma auris did not travel from the only other known case in New York — it appears to have evolved its defenses independently, suggesting that nature is finding its own paths toward the untreatable. The event is not yet a crisis, but it is the kind of quiet signal that history has taught us to take seriously.
Pan-Drug-Resistant Fungus Found in Africa as Candida auris Evolves Beyond Treatment
A 28-year-old woman in Kenya developed a hospital-acquired surgical-site infection with the pan-drug-resistant strain, with mortality rates for C. auris infections reaching 30-50 percent in some cases.
A fungus that survives every standard antifungal weapon
Mark
Why does a single case in Kenya matter so much if pan-drug-resistant Candida auris is still extremely rare?
Mimi
Because it's the second case globally, and it emerged independently—different mutations, different continent. That suggests the resistance isn't a one-off accident. It can evolve in multiple places.
Luke
But we should be careful here. We know it happened twice. We don't know if it's happening a third time right now in a hospital we haven't tested yet. The rarity is real, but so is the blind spot.
Mark
What about the patient herself? Did her treatment cause this?
Mimi
That's the honest answer: we don't know. She received antifungals during her illness, but the researchers didn't have enough detail about doses and timing to say whether those drugs drove the resistance.
Luke
Which means we're left with a gap. The clinical history exists, but it's incomplete. That's not a failure of the reporting—it's a failure of the record-keeping, probably.
Mark
So what happens next? Can doctors treat pan-drug-resistant Candida auris at all?
Mimi
The paper doesn't say. It calls for surveillance and rapid diagnostics, but it doesn't describe what the treatment options actually are for a strain like this.
Luke
That's the real question underneath everything. If you find it, what do you do? And I don't think we have a clear answer yet.
Mark
Is this going to spread?
Mimi
The researchers are warning about the escalating threat, especially in regions with limited access to newer antifungals. But they're also calling for action—better surveillance, faster diagnostics.
Luke
Which means they think it could spread, but they're not saying it will. There's a difference between "this is possible" and "this is happening."
O Pulso
- A 28-year-old woman in Nairobi developed a hospital-acquired infection that no available antifungal drug — not fluconazole, not amphotericin B, not echinocandins, not flucytosine — could touch.
- Genome sequencing revealed a distinct constellation of mutations from the only prior pan-drug-resistant case found in New York in 2022, suggesting this resistance emerged independently on a second continent.
- C. auris already carries a grim record: present in 60+ countries, a 30–50% mortality rate in some settings, and a WHO critical-priority designation — this new strain raises the ceiling on how dangerous it can become.
- Researchers fear that antifungal treatment given to the patient herself may have inadvertently accelerated the pathogen's evolution, turning medicine's own tools against it.
- Scientists are urgently calling for genomic surveillance, rapid diagnostics, and heightened vigilance — especially in regions where access to newer antifungal drugs is already constrained.
In a Nairobi hospital, a young woman's routine surgery became the site of a rare and sobering discovery: a fungus resistant to every antifungal drug medicine currently offers. Only the second case of its kind ever documented, and the first on the African continent, this strain of Candidozyma auris did not travel from the only other known case in New York — it appears to have evolved its defenses independently, suggesting that nature is finding its own paths toward the untreatable. The event is not yet a crisis, but it is the kind of quiet signal that history has taught us to take seriously.
When a 28-year-old woman in Nairobi developed an infection following elective surgery, her doctors discovered something that had been found only once before in the world: a strain of Candidozyma auris resistant to every major class of antifungal medication available. It was the first such case ever documented in Africa.
C. auris is not a new adversary. Identified in 2009, it has since reached more than 60 countries, colonizes hospital environments with unsettling ease, and kills between 30 and 50 percent of those it infects in some documented outbreaks. The WHO named it a critical-priority pathogen in 2022. But pan-drug-resistant versions — strains that defeat all four major antifungal drug classes simultaneously — had until now appeared only once, in New York.
Genome sequencing of the Kenyan isolate revealed the mechanism behind its defenses: mutations in ERG11 and CDR1 blocking azoles, an FKS1 alteration defeating echinocandins, a stop-gain mutation in FUR1 neutralizing flucytosine, and resistance to amphotericin B rounding out a complete pharmacological escape. Crucially, the genetic fingerprint differed from the New York strain, pointing toward independent evolution rather than transmission — meaning this capacity has now emerged in at least two separate lineages.
The woman survived. But the strain she carried left behind a warning. Researchers note that the antifungal drugs used in her treatment may themselves have shaped the pathogen's evolution, a disquieting possibility that underscores the stakes of the microbial arms race. They are calling for urgent investment in genomic surveillance, faster diagnostics, and preparedness in healthcare systems where the newest antifungal options remain out of reach. Pan-drug-resistant C. auris is still rare — but rarity, as this case demonstrates, is not the same as distant.
A 28-year-old woman in Nairobi underwent elective surgery at a hospital and developed an infection at the surgical site. When doctors tested her wound, they found something alarming: a fungus that resists every major antifungal drug available to treat it. The organism is Candidozyma auris, formerly known as Candida auris, and this particular strain represents only the second documented case in the world of complete resistance to all four major classes of antifungal medications.
Candida auris is not new. Scientists first identified it in 2009, and in the years since, it has spread to more than 60 countries across six continents. It thrives in hospital environments, moving easily between patients, and causes invasive infections with mortality rates between 30 and 50 percent in some documented cases. The World Health Organization designated it a critical-priority fungal pathogen in 2022, recognizing both its resistance patterns and its capacity to trigger outbreaks. But until now, the most dangerous version—one that resists all available treatments—had been found only once, in New York in 2022. The Kenyan case is the first documented in Africa.
When researchers sequenced the genome of the fungus recovered from the Nairobi patient, they identified multiple mutations known to confer antifungal resistance. Changes in the ERG11 and CDR1 genes explained resistance to azole drugs like fluconazole. An alteration in the FKS1 gene accounted for resistance to echinocandins such as caspofungin and micafungin. A "stop-gain" mutation in the FUR1 gene rendered the fungus resistant to flucytosine. The strain was also resistant to amphotericin B, one of the oldest and most powerful antifungal weapons in the medical arsenal. Together, these mutations created what researchers call pan-drug resistance—PDR—a state in which the organism can survive exposure to every standard treatment option.
What makes this discovery particularly unsettling is that the genetic profile of the Kenyan isolate differs from the New York strain identified four years earlier. The mutations are different. This suggests that pan-drug resistance may have evolved independently in Kenya rather than being imported from the United States. Whether the patient's own exposure to antifungal medications during her illness selected for this resistance remains unclear; researchers lacked sufficient information about the doses and duration of her treatment to draw that conclusion. But the possibility exists that the very drugs meant to save her life may have inadvertently shaped the evolution of a more dangerous pathogen.
For now, pan-drug-resistant Candida auris remains extraordinarily rare. The fungus has not yet become a widespread threat. But its emergence in a second location, on a different continent, with a different genetic origin, signals something troubling: this organism has already demonstrated its capacity to move through hospitals, acquire resistance, and adapt in response to treatment. Researchers are calling for urgent action—stronger surveillance of fungal genomes in healthcare settings, rapid diagnostic capacity to identify highly resistant strains before they spread, and heightened vigilance in regions where access to newer antifungal drugs is already limited. The woman in Nairobi survived her infection, but the strain she carried represents a warning that the microbial arms race continues, and the most dangerous adversaries do not need to be common to be consequential.
Citações Notáveis
The escalating threat of untreatable fungal infections and the need for stronger surveillance of fungal genomes and rapid diagnostic capacity to mitigate the spread of highly resistant C. auris lineages in healthcare settings.— Researchers in the study
Quer a matéria completa?
Leia o original em sciencealert.com ↗